PTD-DBM
Based on 1 Customer Validation
PTD-DBM is a CXXC5-Dvl protein-protein interaction inhibitor and also a Wnt/β-catenin pathway activator. PTD-DBM interferes with the Dvl-binding function of CXXC5, disrupts the negative feedback regulation of the Wnt/β-catenin pathway, induces β-catenin expression and nuclear translocation, and increases the production of type I collagen, α-smooth muscle actin and endothelin-1. PTD-DBM is applicable to studies related to androgenetic alopecia and skin wound healing.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 96.12%
- CAS 番号: 1609454-11-6
- 分子式: C124H225N61O28S2
- 分子量:3082.64
-
保管条件:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
PTD-DBM (10 μM; 72 h) restores Wnt/β-catenin signaling and proliferation marker expression in PGD2-treated HaCaT cells[1].
PTD-DBM (2-10 μM; 24 h-2 d) activates Wnt/β-catenin signaling and promotes myofibroblast differentiation, collagen production, collagen gel contraction, and cell migration in human dermal fibroblasts in vitro in a concentration-dependent manner, with effects abolished by β-catenin knockdown or bosentan, and synergistically enhanced by co-treatment with Wnt3a[3].
PTD-DBM (2 μM; 2 d) synergistically enhances Wnt/β-catenin activation with Wnt3a in HaCaT keratinocytes, increasing β-catenin expression[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
PTD-DBM (10 mM; topical; daily; 7 to 21 or 25 days post-wounding) restores PGD2-impaired wound-induced hair follicle neogenesis in C57BL/6N mice by reactivating Wnt/β-catenin signaling and regenerative markers, recovering neogenic follicle counts to control levels[1].
PTD-DBM (100 μM; topical; daily; 11 days) alone accelerates cutaneous wound healing and increases collagen production in mice, while PTD-DBM (100 μM + 500 mM VPA; topical; daily; 11 days) co-treatment with VPA synergistically enhances these effects, with no induction of oncogenic markers c-Myc or cyclin D1[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6N wild-type (7-week-old male; dorsal skin depilation-induced hair cycle synchronization, topical PGD2 exposure-induced hair growth suppression)[1]
-
Dosage:10 mM
-
Administration:topical; every other day; 8 to 12 or 20 days post-depilation
-
Result:Restored PGD2-suppressed hair shaft length to levels comparable to untreated control mice.
Restored nuclear β-catenin fluorescence intensity and PCNA protein expression in skin tissues, which were reduced by PGD2 exposure.
-
Animal Model:C57BL/6N wild-type (3-week-old; full-thickness dorsal skin wound, topical PGD2 exposure-induced hair follicle regeneration suppression)[1]
-
Dosage:10 mM
-
Administration:topical; daily; 7 to 21 or 25 days post-wounding
-
Result:Restored PGD2-suppressed neogenic hair follicle counts (measured via ALP staining) to levels comparable to untreated control mice.
Induced expression of WIHN markers (fgf9, keratin 17), as well as β-catenin and PCNA protein expression in wounded skin tissues, which were reduced by PGD2 exposure.
-
Animal Model:C3H mice (7-week-old male)[3]
-
Dosage:100 μM (single-agent); 100 μM + 500 mM VPA (combination)
-
Administration:topical; daily; 11 days
-
Result:Accelerated cutaneous wound healing to a degree comparable to EGF treatment, reaching ~90% wound closure by day 12.
Increased β-catenin levels in wound tissue, and induced increases in keratin 14, collagen I, PCNA, and endothelin-1 expression in wound keratinocytes and fibroblasts.
Induced significantly greater increases in β-catenin, keratin 14, collagen I, PCNA, endothelin-1, and phosphorylated ERK in wound tissue compared to single-agent treatments or EGF.
化学情報
-
CAS 番号 1609454-11-6
-
性状 Solid
-
分子量 3082.64
-
分子式 C124H225N61O28S2
-
Color White to off-white
-
配列
Arg-Arg-Arg-Arg-Arg-Arg-Arg-Arg-Gly-Gly-Gly-Gly-Arg-Lys-Thr-Gly-His-Gln-Ile-Cys-Lys-Phe-Arg-Lys-Cys
-
シーケンスの短縮
RRRRRRRRGGGGRKTGHQICKFRKC
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶剤 & 溶解度
H2O : ≥ 100 mg/mL (32.44 mM)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (284 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Ryu YC, et al. CXXC5 Mediates DHT-Induced Androgenetic Alopecia via PGD2. Cells. 2023;12(4):555. Published 2023 Feb 9. [Content Brief]
[2]. Kim E, et al. Inhibiting the cytosolic function of CXXC5 accelerates diabetic wound healing by enhancing angiogenesis and skin repair. Exp Mol Med. 2023;55(8):1770-1782. [Content Brief]
[3]. Lee SH, et al. The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing. J Exp Med. 2015;212(7):1061-1080. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 0.3244 mL | 1.6220 mL | 3.2440 mL | 8.1099 mL |
| 5 mM | 0.0649 mL | 0.3244 mL | 0.6488 mL | 1.6220 mL | |
| 10 mM | 0.0324 mL | 0.1622 mL | 0.3244 mL | 0.8110 mL | |
| 15 mM | 0.0216 mL | 0.1081 mL | 0.2163 mL | 0.5407 mL | |
| 20 mM | 0.0162 mL | 0.0811 mL | 0.1622 mL | 0.4055 mL | |
| 25 mM | 0.0130 mL | 0.0649 mL | 0.1298 mL | 0.3244 mL | |
| 30 mM | 0.0108 mL | 0.0541 mL | 0.1081 mL | 0.2703 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Powered by Bioz